Trending...
- Fenix Consulting Group Expands Orange County Office to Meet Growing Client Demand
- Broadway Smile Boutique Unveils Modern Website for Enhanced Patient Experience
- "Latino Leaders Speak: Personal Stories of Struggle and Triumph, Volume II" Documents the Truth About Latino Excellence and Impact on American Society
Despite $280 billion annually poured into psychiatric hospitals, forced treatment, and community programs, outcomes are abysmal. Governments must review costs and results before sinking more funds into failed systems.
LOS ANGELES - PrAtlas -- By CCHR International
With $280 billion invested annually in psychiatric hospitals and treatment—and billions more paid out to treat the damage they cause—the mental health watchdog Citizens Commission on Human Rights International (CCHR) warns that continuing to fund the system without accountability is like pouring water into a sieve or patching a sinking ship with paper.
For-profit behavioral chains now control nearly one-third of all freestanding psychiatric beds in the U.S., up from less than one-quarter in 2011, while government-owned beds have fallen from 64% to 48%.[1] These corporate providers have been repeatedly exposed for abuse and neglect. Since 2015, over 120 youth treatment centers have closed after scandals, lawsuits, or safety violations, including sexual assault of patients and restraint deaths.
Meanwhile, proponents of "bringing back" large state-run mental institutions ignore history. When state hospitals were shut down in the 1960s, it was not because psychiatry had reformed but because conditions were so appalling that they became a national scandal, according to CCHR, which was established in 1969. It documented how psychiatry's promised "community mental health" solution merely shifted abuse from one setting to another, while psychiatrists expanded their reach and funding by prescribing more drugs to more people.
The numbers prove the futility: federal funding for community mental health centers jumped more than 160% from $143 million in 1969 to $372 million projected for 2025.[2] Yet outcomes have not improved.
The Iatrogenic Drug Damage and Profits
More on PrAtlas
Iatrogenic harm—injuries caused by medical treatment itself—is a hallmark of modern psychiatric drugging, driving up health care costs and fueling a cycle of permanent disability and profit.
Psychiatric drugs can cause profound neurological and nervous system damage, including injury to the brain, spinal cord, and peripheral nerves. Adverse effects include seizures, paralysis, loss of coordination and muscle strength, numbness, loss of consciousness, and an increased risk of stroke. Even widely prescribed SSRI antidepressants can trigger serotonin syndrome, a potentially lethal reaction marked by muscle rigidity, high fever, seizures, irregular heartbeat, organ failure. Side effects also include suicide and aggression. Disturbingly, many of these side effects mimic or worsen the very "mental disorders" the drugs are marketed to treat—drug-induced agitation or anxiety is frequently mislabeled as a "mood disorder," resulting in yet more prescriptions, escalating risks and costs.[7]
Antipsychotics are particularly devastating. They cause tardive dyskinesia (TD)—permanent, involuntary muscle movements—in 20% to 50% of those prescribed them. They also produce akathisia, a state of unbearable inner restlessness that can drive violent behavior, along with insulin resistance, cardiac complications, and severe metabolic disturbances.[8]
Rather than halting prescriptions when such damage occurs, psychiatry has created an entire secondary industry to "treat" drug-induced conditions. For example, the same manufacturers that profit from selling antipsychotics also profit from selling drugs to suppress TD symptoms.[9] By 2024, the TD treatment market had reached $3.6 billion and is expected to climb to $5.2 billion within five years.
"This demonstrates a grim business model: the continuation of prescribing psychotropic drugs known to cause permanent harm ensures a growing market for drugs to treat those harms—none of which is improving mental health in the country," says Jan Eastgate, president of CCHR International.
Far from healing, this revolving door of iatrogenic injury and psychiatric-pharmaceutical profit ensures patients remain trapped in a cycle of dependency, disability, and escalating costs—all while psychiatric providers reap billions.
"This is not care—it is coercion weaponized under the false banner of help," Eastgate states. "The biomedical model psychiatry clings to is not only ineffective—it is harmful and costly."
More on PrAtlas
CCHR says governments must stop treating the funding of psychiatry as unquestionable good. Before infusing more billions into state hospitals, private chains, or mandated treatment programs, there must be a hard audit of costs versus outcomes. To do otherwise is refilling a leaking bucket—it guarantees waste and perpetuates harm.
Instead of repeating failed approaches, policymakers must demand accountability, end coercive practices, and reject psychiatry's biomedical model that has only deepened America's crisis. Until then, every taxpayer dollar poured into this system is not just wasted—it fuels human suffering and ensures a further waste of funds and, most importantly, lives.
CCHR, established over 50 years ago by the Church of Scientology and Professor of psychiatry, Thomas Szasz, has helped achieve hundreds of mental health reforms in the six continents it operates in.
Sources:
[1] bhbusiness.com/2025/09/23/psychiatric-beds-increasingly-controlled-by-for-profit-giants/
[2] "Total expenditures … by type of mental health organization: United States, selected years, 1969-1983," Mental Health, United States, 1987, U.S. Department of Health and Human Services, p. 5; bhbusiness.com/2022/03/28/white-house-budget-proposes-to-transform-mental-healthcare-allocates-4-8b-to-related-initiatives/
[3] pmc.ncbi.nlm.nih.gov/articles/PMC8355085/
[4] time.com/6308096/therapy-mental-health-worse-us/
[5] www.npr.org/sections/health-shots/2023/12/21/1219628362/well-intentioned-mental-health-courts-can-struggle-to-live-up-to-their-goals
[6] www.cchrint.org/2024/11/22/280b-invested-mental-health-worsens-cchr-demands-audit-and-accountability/, citing link.springer.com/article/10.1007/s00127-014-0912-2
[7] Adam O'Brien, Ph.D., "The Double-Edged Sword: Medication Potency, Side Effects, and the Mind," Wounded Healers Institute, 24 July 2025
[8] www.ncbi.nlm.nih.gov/pmc/articles/PMC5472076/; https://www.medprodisposal.com/akathisia-15-things-to-know-about-this-horrible-condition/
[9] www.cchrint.org/2021/10/11/consumers-beware-of-antipsychotics-long-term-debilitating-effects/; www.rxlist.com/ingrezza-drug.htm#professional; www.drugs.com/sfx/ingrezza-side-effects.html
With $280 billion invested annually in psychiatric hospitals and treatment—and billions more paid out to treat the damage they cause—the mental health watchdog Citizens Commission on Human Rights International (CCHR) warns that continuing to fund the system without accountability is like pouring water into a sieve or patching a sinking ship with paper.
For-profit behavioral chains now control nearly one-third of all freestanding psychiatric beds in the U.S., up from less than one-quarter in 2011, while government-owned beds have fallen from 64% to 48%.[1] These corporate providers have been repeatedly exposed for abuse and neglect. Since 2015, over 120 youth treatment centers have closed after scandals, lawsuits, or safety violations, including sexual assault of patients and restraint deaths.
Meanwhile, proponents of "bringing back" large state-run mental institutions ignore history. When state hospitals were shut down in the 1960s, it was not because psychiatry had reformed but because conditions were so appalling that they became a national scandal, according to CCHR, which was established in 1969. It documented how psychiatry's promised "community mental health" solution merely shifted abuse from one setting to another, while psychiatrists expanded their reach and funding by prescribing more drugs to more people.
The numbers prove the futility: federal funding for community mental health centers jumped more than 160% from $143 million in 1969 to $372 million projected for 2025.[2] Yet outcomes have not improved.
- Between 1999 and 2019, psychotropic drugs were implicated in 51,446 deaths and nearly 650,000 overdoses, while the annual death rate from these drugs more than tripled.[3]
- Suicide rates have risen 30% since 2000.[4]
- Mental health courts and community treatment orders have reinforced failure. As of 2022, over 650 such courts have been established, but research shows they do not improve mental health, reduce reoffending, or save costs. Instead, they are often expensive, resource-intensive, and punitive—where if someone misses taking a mandated psychiatric drug, it can mean jail time.[5]
- Psychiatric drugs make suicide nearly six times more likely, while psychiatric hospitalization raises the risk of self-inflicted death an alarming 44 times.[6]
The Iatrogenic Drug Damage and Profits
More on PrAtlas
- UK Financial Ltd Completes Full Ecosystem Conversion With Three New ERC-3643 SEC-Ready Tokens As MCAT Deadline Closes Tonight
- AI Real Estate Company Quietly Building a National Powerhouse: reAlpha Tech Corp. (N A S D A Q: AIRE)
- Inkdnylon Expands National Uniform Embroidery Services
- Appliance EMT Expands Appliance Repair Services to Portland, OR and Vancouver, WA
- Next Week: The World's Best Young Pianists Arrive in Music City for the 2025 Nashville International Chopin Piano Competition
Iatrogenic harm—injuries caused by medical treatment itself—is a hallmark of modern psychiatric drugging, driving up health care costs and fueling a cycle of permanent disability and profit.
Psychiatric drugs can cause profound neurological and nervous system damage, including injury to the brain, spinal cord, and peripheral nerves. Adverse effects include seizures, paralysis, loss of coordination and muscle strength, numbness, loss of consciousness, and an increased risk of stroke. Even widely prescribed SSRI antidepressants can trigger serotonin syndrome, a potentially lethal reaction marked by muscle rigidity, high fever, seizures, irregular heartbeat, organ failure. Side effects also include suicide and aggression. Disturbingly, many of these side effects mimic or worsen the very "mental disorders" the drugs are marketed to treat—drug-induced agitation or anxiety is frequently mislabeled as a "mood disorder," resulting in yet more prescriptions, escalating risks and costs.[7]
Antipsychotics are particularly devastating. They cause tardive dyskinesia (TD)—permanent, involuntary muscle movements—in 20% to 50% of those prescribed them. They also produce akathisia, a state of unbearable inner restlessness that can drive violent behavior, along with insulin resistance, cardiac complications, and severe metabolic disturbances.[8]
Rather than halting prescriptions when such damage occurs, psychiatry has created an entire secondary industry to "treat" drug-induced conditions. For example, the same manufacturers that profit from selling antipsychotics also profit from selling drugs to suppress TD symptoms.[9] By 2024, the TD treatment market had reached $3.6 billion and is expected to climb to $5.2 billion within five years.
"This demonstrates a grim business model: the continuation of prescribing psychotropic drugs known to cause permanent harm ensures a growing market for drugs to treat those harms—none of which is improving mental health in the country," says Jan Eastgate, president of CCHR International.
Far from healing, this revolving door of iatrogenic injury and psychiatric-pharmaceutical profit ensures patients remain trapped in a cycle of dependency, disability, and escalating costs—all while psychiatric providers reap billions.
"This is not care—it is coercion weaponized under the false banner of help," Eastgate states. "The biomedical model psychiatry clings to is not only ineffective—it is harmful and costly."
More on PrAtlas
- Revenue Optics Builds Out Its Dedicated Sales Recruiting Firm with Strategic Addition of Christine Schafer
- Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
- Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
- Flower City Tattoo Convention Draws Record Attendance in Rochester, NY
- KIKO NATION TOKEN (Official Release)
CCHR says governments must stop treating the funding of psychiatry as unquestionable good. Before infusing more billions into state hospitals, private chains, or mandated treatment programs, there must be a hard audit of costs versus outcomes. To do otherwise is refilling a leaking bucket—it guarantees waste and perpetuates harm.
Instead of repeating failed approaches, policymakers must demand accountability, end coercive practices, and reject psychiatry's biomedical model that has only deepened America's crisis. Until then, every taxpayer dollar poured into this system is not just wasted—it fuels human suffering and ensures a further waste of funds and, most importantly, lives.
CCHR, established over 50 years ago by the Church of Scientology and Professor of psychiatry, Thomas Szasz, has helped achieve hundreds of mental health reforms in the six continents it operates in.
Sources:
[1] bhbusiness.com/2025/09/23/psychiatric-beds-increasingly-controlled-by-for-profit-giants/
[2] "Total expenditures … by type of mental health organization: United States, selected years, 1969-1983," Mental Health, United States, 1987, U.S. Department of Health and Human Services, p. 5; bhbusiness.com/2022/03/28/white-house-budget-proposes-to-transform-mental-healthcare-allocates-4-8b-to-related-initiatives/
[3] pmc.ncbi.nlm.nih.gov/articles/PMC8355085/
[4] time.com/6308096/therapy-mental-health-worse-us/
[5] www.npr.org/sections/health-shots/2023/12/21/1219628362/well-intentioned-mental-health-courts-can-struggle-to-live-up-to-their-goals
[6] www.cchrint.org/2024/11/22/280b-invested-mental-health-worsens-cchr-demands-audit-and-accountability/, citing link.springer.com/article/10.1007/s00127-014-0912-2
[7] Adam O'Brien, Ph.D., "The Double-Edged Sword: Medication Potency, Side Effects, and the Mind," Wounded Healers Institute, 24 July 2025
[8] www.ncbi.nlm.nih.gov/pmc/articles/PMC5472076/; https://www.medprodisposal.com/akathisia-15-things-to-know-about-this-horrible-condition/
[9] www.cchrint.org/2021/10/11/consumers-beware-of-antipsychotics-long-term-debilitating-effects/; www.rxlist.com/ingrezza-drug.htm#professional; www.drugs.com/sfx/ingrezza-side-effects.html
Source: Citizens Commission on Human Rights International
Filed Under: Consumer, Medical, Health, Government, Science, Citizens Commission On Human Rights, CCHR International
0 Comments
Latest on PrAtlas
- Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
- Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
- Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
- America's Most Festive Garages Wanted for Garage.com's 2025 Holiday Contest
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
- BEC Technologies Expands MX-220 5G Industrial Router Series for Edge Connectivity
- "Latino Leaders Speak: Personal Stories of Struggle and Triumph, Volume II" Documents the Truth About Latino Excellence and Impact on American Society
- Broadway Smile Boutique Unveils Modern Website for Enhanced Patient Experience
- Fenix Consulting Group Expands Orange County Office to Meet Growing Client Demand
- Signature Smiles Dental Group Unveils New User-Friendly Website
- CCHR: New Data Shows Millions of U.S. Children Caught in Escalating Psychiatric Polypharmacy
- QwickContractReview.com Launches $19 Contract Review Service to Protect Consumers from Hidden Contract Risks
